C07J 7/0065
Substituted in position 20 by an oh group free esterified or etherified
Official title: {substituted in position 20 by an OH group free esterified or etherified}
C07J7/0065 (Substituted in position 20 by an oh group free esterified or etherified) appears on 95 US grants and 112 published applications in this corpus.
Search patents in C07J- Granted patents
- 95
- Published applications
- 112
- Assignees
- 50
- Inventors
- 159
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 4 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 0 |
| 2002 | 3 | 3 |
| 2003 | 1 | 1 |
| 2004 | 0 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 5 |
| 2014 | 1 | 6 |
| 2015 | 1 | 4 |
| 2016 | 5 | 8 |
| 2017 | 1 | 8 |
| 2018 | 4 | 7 |
| 2019 | 7 | 6 |
| 2020 | 5 | 9 |
| 2021 | 3 | 14 |
| 2022 | 7 | 7 |
| 2023 | 7 | 8 |
| 2024 | 6 | 12 |
| 2025 | 2 | 6 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for treating CNS disorders27 Jan 2026US 12,534,495 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions and uses thereof18 Nov 2025US 12,473,327 B2Sage Therapeutics, Inc.
- 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof21 Jan 2025US 12,201,640 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof29 Oct 2024US 12,129,275 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof27 Aug 2024US 12,071,453 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof30 Apr 2026US 2026/0116911 A1Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof30 Apr 2026US 2026/0116912 A1Sage Therapeutics, Inc.
- Compositions and methods for treating cns disorders9 Apr 2026US 2026/0098053 A1Sage Therapeutics, Inc.
- 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof16 Oct 2025US 2025/0319106 A1Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof14 Aug 2025US 2025/0257092 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series70US 5,232,917 AUniversity of Southern California · 1993
- Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments59US 5,512,558 AHoechst Aktiengesellschaft · 1996
- 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof59US 9,512,165 B2Sage Therapeutics, Inc. · 2016
- 19-NOR neuroactive steroids and methods of use thereof49US 9,365,611 B2Sage Therapeutics, Inc. · 2016
- Process for the preparation of 17.alpha.-hydroxyprogesterones and corticoids from androstenes48US 4,041,055 AThe Upjohn Company · 1977